

Lisa E Hensley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7749863/publications.pdf>

Version: 2024-02-01

222
papers

21,874
citations

7568

77
h-index

10445

139
g-index

230
all docs

230
docs citations

230
times ranked

19928
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. <i>New England Journal of Medicine</i> , 2019, 381, 2293-2303.	27.0	1,171
2	Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. <i>Nature Medicine</i> , 2005, 11, 786-790.	30.7	607
3	Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. <i>Nature</i> , 2011, 477, 344-348.	27.8	601
4	Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16262-16267.	7.1	580
5	Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4885-4893.	3.2	564
6	Pathogenesis of Ebola Hemorrhagic Fever in <i>Cynomolgus</i> Macaques. <i>American Journal of Pathology</i> , 2003, 163, 2347-2370.	3.8	543
7	Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. <i>Lancet, The</i> , 2010, 375, 1896-1905.	13.7	414
8	Molecular Evidence of Sexual Transmission of Ebola Virus. <i>New England Journal of Medicine</i> , 2015, 373, 2448-2454.	27.0	380
9	Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. <i>Lancet, The</i> , 2003, 362, 1953-1958.	13.7	362
10	Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. <i>MBio</i> , 2014, 5, e00884-14.	4.1	359
11	Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 18030-18035.	7.1	344
12	Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1088-1099.	3.2	344
13	Mechanisms Underlying Coagulation Abnormalities in Ebola Hemorrhagic Fever: Overexpression of Tissue Factor in Primate Monocytes/Macrophages Is a Key Event. <i>Journal of Infectious Diseases</i> , 2003, 188, 1618-1629.	4.0	336
14	Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12995-13000.	7.1	336
15	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. <i>Nature Medicine</i> , 2014, 20, 1126-1129.	30.7	311
16	Pathogenesis of Ebola Hemorrhagic Fever in Primate Models. <i>American Journal of Pathology</i> , 2003, 163, 2371-2382.	3.8	292
17	FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection. <i>Science Translational Medicine</i> , 2013, 5, 190ra79.	12.4	285
18	Apoptosis Induced In Vitro and In Vivo During Infection by Ebola and Marburg Viruses. <i>Laboratory Investigation</i> , 2000, 80, 171-186.	3.7	282

#	ARTICLE	IF	CITATIONS
19	Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12123-12128.	7.1	276
20	Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone. <i>Cell</i> , 2015, 161, 1516-1526.	28.9	275
21	Evaluation of candidate vaccine approaches for MERS-CoV. <i>Nature Communications</i> , 2015, 6, 7712.	12.8	258
22	Effective Post-Exposure Treatment of Ebola Infection. <i>PLoS Pathogens</i> , 2007, 3, e2.	4.7	246
23	Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus. <i>Journal of Virology</i> , 2009, 83, 7296-7304.	3.4	241
24	The Pathology of Experimental Aerosolized Monkeypox Virus Infection in Cynomolgus Monkeys (<i>Macaca fascicularis</i>). <i>Laboratory Investigation</i> , 2001, 81, 1581-1600.	3.7	237
25	Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. <i>Immunology Letters</i> , 2002, 80, 169-179.	2.5	232
26	Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference. <i>Journal of Infectious Diseases</i> , 2006, 193, 1650-1657.	4.0	232
27	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. <i>Cell</i> , 2015, 162, 738-750.	28.9	230
28	Development of a New Vaccine for the Prevention of Lassa Fever. <i>PLoS Medicine</i> , 2005, 2, e183.	8.4	223
29	Genomic Variability of Monkeypox Virus among Humans, Democratic Republic of the Congo. <i>Emerging Infectious Diseases</i> , 2014, 20, 232-9.	4.3	219
30	A broad-spectrum antiviral targeting entry of enveloped viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3157-3162.	7.1	214
31	A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. <i>Science Translational Medicine</i> , 2015, 7, 290ra89.	12.4	212
32	Correction to Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia. <i>MBio</i> , 2014, 5, .	4.1	209
33	CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. <i>Nature Medicine</i> , 2011, 17, 1128-1131.	30.7	200
34	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	27.0	199
35	Comprehensive Panel of Real-Time TaqMan,¢ Polymerase Chain Reaction Assays for Detection and Absolute Quantification of Filoviruses, Arenaviruses, and New World Hantaviruses. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 954-960.	1.4	195
36	Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 905-912.	9.1	193

#	ARTICLE	IF	CITATIONS
37	Interferon- \hat{I}^2 and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. <i>Journal of General Virology</i> , 2014, 95, 571-577.	2.9	191
38	Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. <i>Vaccine</i> , 2008, 26, 6894-6900.	3.8	179
39	Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates. <i>PLoS Pathogens</i> , 2008, 4, e1000225.	4.7	177
40	Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. <i>Journal of Virology</i> , 2011, 85, 4222-4233.	3.4	176
41	Interferon- \hat{I}^2 1a and SARS Coronavirus Replication. <i>Emerging Infectious Diseases</i> , 2004, 10, 317-319.	4.3	173
42	Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. <i>Lancet, The</i> , 2006, 367, 1399-1404.	13.7	166
43	From The Cover: Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15196-15200.	7.1	163
44	Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. <i>SpringerPlus</i> , 2015, 4, 709.	1.2	163
45	Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. <i>Drugs</i> , 2017, 77, 1935-1966.	10.9	156
46	Depletion of Peripheral Blood T Lymphocytes and NK Cells During the Course of Ebola Hemorrhagic Fever in Cynomolgus Macaques. <i>Viral Immunology</i> , 2004, 17, 390-400.	1.3	151
47	Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever. <i>Journal of Infectious Diseases</i> , 2007, 196, S390-S399.	4.0	141
48	Haematological, Biochemical and Coagulation Changes in Mice, Guinea-pigs and Monkeys Infected with a Mouse-adapted Variant of Ebola Zaire Virus. <i>Journal of Comparative Pathology</i> , 2001, 125, 243-253.	0.4	139
49	Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2620-2625.	3.2	139
50	Management of Accidental Exposure to Ebola Virus in the Biosafety Level 4 Laboratory, Hamburg, Germany. <i>Journal of Infectious Diseases</i> , 2011, 204, S785-S790.	4.0	138
51	Recombinant Vesicular Stomatitis Virus Vector Mediates Postexposure Protection against Sudan Ebola Hemorrhagic Fever in Nonhuman Primates. <i>Journal of Virology</i> , 2008, 82, 5664-5668.	3.4	136
52	Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples. <i>Genome Biology</i> , 2014, 15, 519.	8.8	129
53	The pathogenesis of Rift Valley fever virus in the mouse model. <i>Virology</i> , 2010, 407, 256-267.	2.4	122
54	Real-Time Sequence-Validated Loop-Mediated Isothermal Amplification Assays for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). <i>PLoS ONE</i> , 2015, 10, e0123126.	2.5	122

#	ARTICLE	IF	CITATIONS
55	Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences. <i>Journal of Virology</i> , 2012, 86, 3284-3292.	3.4	114
56	Cross-Protection against Marburg Virus Strains by Using a Live, Attenuated Recombinant Vaccine. <i>Journal of Virology</i> , 2006, 80, 9659-9666.	3.4	112
57	Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment with Recombinant Nematode Anticoagulant Protein c2. <i>Journal of Infectious Diseases</i> , 2007, 196, S372-S381.	4.0	112
58	ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1817-1822.	3.2	112
59	From The Cover: The host response to smallpox: Analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15190-15195.	7.1	111
60	Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. <i>Expert Reviews in Molecular Medicine</i> , 2004, 6, 1-24.	3.9	109
61	Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species. <i>PLoS Pathogens</i> , 2010, 6, e1000904.	4.7	106
62	A Longitudinal Study of Ebola Sequelae in Liberia. <i>New England Journal of Medicine</i> , 2019, 380, 924-934.	27.0	104
63	Human polyclonal immunoglobulin G from transchromosomal bovines inhibits MERS-CoV in vivo. <i>Science Translational Medicine</i> , 2016, 8, 326ra21.	12.4	102
64	Pathogenesis of lassa fever in cynomolgus macaques. <i>Virology Journal</i> , 2011, 8, 205.	3.4	101
65	Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time. <i>Nature Communications</i> , 2020, 11, 4131.	12.8	101
66	Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. <i>Archives of Virology</i> , 2013, 158, 301-311.	2.1	99
67	Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome. <i>PLoS Medicine</i> , 2006, 3, e149.	8.4	98
68	The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005540.	3.0	97
69	Capturing sequence diversity in metagenomes with comprehensive and scalable probe design. <i>Nature Biotechnology</i> , 2019, 37, 160-168.	17.5	96
70	Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1567.	3.0	95
71	Interferon- β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever. <i>Journal of Infectious Diseases</i> , 2013, 208, 310-318.	4.0	93
72	MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. <i>PLoS ONE</i> , 2018, 13, e0194868.	2.5	93

#	ARTICLE	IF	CITATIONS
73	Inhibition of heat-shock protein 90 reduces Ebola virus replication. <i>Antiviral Research</i> , 2010, 87, 187-194.	4.1	92
74	Pathology of Experimental Aerosol Zaire Ebolavirus Infection in Rhesus Macaques. <i>Veterinary Pathology</i> , 2013, 50, 514-529.	1.7	87
75	Evolution and Spread of Ebola Virus in Liberia, 2014–2015. <i>Cell Host and Microbe</i> , 2015, 18, 659-669.	11.0	87
76	Persistent Infection Promotes Cross-Species Transmissibility of Mouse Hepatitis Virus. <i>Journal of Virology</i> , 1999, 73, 638-649.	3.4	82
77	Formation of Antiviral Cytoplasmic Granules during Orthopoxvirus Infection. <i>Journal of Virology</i> , 2011, 85, 1581-1593.	3.4	81
78	The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. <i>Genome Biology</i> , 2007, 8, R174.	9.6	80
79	Pathogenesis of Marburg Hemorrhagic Fever in <i>Cynomolgus</i> Macaques. <i>Journal of Infectious Diseases</i> , 2011, 204, S1021-S1031.	4.0	80
80	Lymphocyte Death in a Mouse Model of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2007, 196, S296-S304.	4.0	79
81	Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia. <i>Emerging Infectious Diseases</i> , 2015, 21, 1135-1143.	4.3	79
82	Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics. <i>Cell</i> , 2020, 183, 1383-1401.e19.	28.9	79
83	Postexposure Treatment of Marburg Virus Infection. <i>Emerging Infectious Diseases</i> , 2010, 16, 1119-1122.	4.3	78
84	Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. <i>Virology Journal</i> , 2010, 7, 279.	3.4	77
85	Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. <i>Antiviral Research</i> , 2011, 90, 70-79.	4.1	77
86	Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus. <i>Journal of Virological Methods</i> , 2015, 223, 13-18.	2.1	75
87	In Vitro and In Vivo Characterization of Recombinant Ebola Viruses Expressing Enhanced Green Fluorescent Protein. <i>Journal of Infectious Diseases</i> , 2007, 196, S313-S322.	4.0	74
88	Stunned Silence: Gene Expression Programs in Human Cells Infected with Monkeypox or Vaccinia Virus. <i>PLoS ONE</i> , 2011, 6, e15615.	2.5	73
89	Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. <i>Antiviral Research</i> , 2014, 107, 102-109.	4.1	69
90	One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. <i>Journal of Virology</i> , 2017, 91, .	3.4	69

#	ARTICLE	IF	CITATIONS
91	Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates. PLoS ONE, 2014, 9, e94355.	2.5	67
92	3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology, 2016, 490, 49-58.	2.4	67
93	Sporogonic Development of Plasmodium yoelii in Five Anopheline Species. Journal of Parasitology, 1994, 80, 674.	0.7	63
94	Reduced evolutionary rate in reemerged Ebola virus transmission chains. Science Advances, 2016, 2, e1600378.	10.3	62
95	A Novel Respiratory Model of Infection with Monkeypox Virus in Cynomolgus Macaques. Journal of Virology, 2011, 85, 4898-4909.	3.4	61
96	Ebola Virus Exploits a Monocyte Differentiation Program To Promote Its Entry. Journal of Virology, 2013, 87, 3801-3814.	3.4	60
97	Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Archives of Virology, 2014, 159, 1229-37.	2.1	59
98	Ebola and Its Control in Liberia, 2014–2015. Emerging Infectious Diseases, 2016, 22, 169-177.	4.3	59
99	Development of a Novel Nonhuman Primate Model for Rift Valley Fever. Journal of Virology, 2012, 86, 2109-2120.	3.4	57
100	Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease. New England Journal of Medicine, 2021, 384, 1240-1247.	27.0	57
101	Pathologic Findings Associated with Delayed Death in Nonhuman Primates Experimentally Infected with Zaire Ebola Virus. Journal of Infectious Diseases, 2007, 196, S323-S328.	4.0	56
102	Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cellular Microbiology, 2010, 12, 148-157.	2.1	56
103	Using Remote Sensing to Map the Risk of Human Monkeypox Virus in the Congo Basin. EcoHealth, 2011, 8, 14-25.	2.0	55
104	Aerosol Exposure to Rift Valley Fever Virus Causes Earlier and More Severe Neuropathology in the Murine Model, which Has Important Implications for Therapeutic Development. PLoS Neglected Tropical Diseases, 2013, 7, e2156.	3.0	55
105	Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Archives of Virology, 2013, 158, 1425-1432.	2.1	54
106	In vivo Ebola virus infection leads to a strong innate response in circulating immune cells. BMC Genomics, 2016, 17, 707.	2.8	54
107	Comparative Analysis of Viral Gene Expression Programs during Poxvirus Infection: A Transcriptional Map of the Vaccinia and Monkeypox Genomes. PLoS ONE, 2008, 3, e2628.	2.5	54
108	Ebola and Marburg Viruses: Pathogenesis and Development of Countermeasures. Current Molecular Medicine, 2005, 5, 761-772.	1.3	52

#	ARTICLE	IF	CITATIONS
109	Ebola Virus Neutralizing Antibodies Detectable in Survivors of the Yambuku, Zaire Outbreak 40 Years after Infection. <i>Journal of Infectious Diseases</i> , 2018, 217, 223-231.	4.0	52
110	Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication. <i>MBio</i> , 2016, 7, .	4.1	50
111	Viral Hemorrhagic Fever Diagnostics. <i>Clinical Infectious Diseases</i> , 2016, 62, 214-219.	5.8	50
112	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. <i>Viruses</i> , 2014, 6, 3663-3682.	3.3	49
113	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. <i>Journal of Infectious Diseases</i> , 2018, 218, S672-S678.	4.0	49
114	Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1015-1024.	9.1	48
115	Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. <i>Virology</i> , 2015, 485, 422-430.	2.4	47
116	Cytokine modulation correlates with severity of monkeypox disease in humans. <i>Journal of Clinical Virology</i> , 2015, 63, 42-45.	3.1	46
117	Potential Vaccines and Post-Exposure Treatments for Filovirus Infections. <i>Viruses</i> , 2012, 4, 1619-1650.	3.3	44
118	The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. <i>Antiviral Research</i> , 2016, 125, 71-78.	4.1	44
119	Ebola Virus Genome Plasticity as a Marker of Its Passaging History: A Comparison of In Vitro Passaging to Non-Human Primate Infection. <i>PLoS ONE</i> , 2012, 7, e50316.	2.5	44
120	Cellular Immune Response to Marburg Virus Infection in Cynomolgus Macaques. <i>Viral Immunology</i> , 2008, 21, 355-364.	1.3	43
121	Evolution of Ebola Virus Disease from Exotic Infection to Global Health Priority, Liberia, Mid-2014. <i>Emerging Infectious Diseases</i> , 2015, 21, 578-584.	4.3	43
122	Varicella Coinfection in Patients with Active Monkeypox in the Democratic Republic of the Congo. <i>EcoHealth</i> , 2017, 14, 564-574.	2.0	42
123	Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: Case Report. <i>Virology Journal</i> , 2011, 8, 314.	3.4	41
124	Susceptibility of Marmosets (<i>Callithrix jacchus</i>) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. <i>PLoS ONE</i> , 2015, 10, e0131742.	2.5	41
125	DRBP76 Associates With Ebola Virus VP35 and Suppresses Viral Polymerase Function. <i>Journal of Infectious Diseases</i> , 2011, 204, S911-S918.	4.0	40
126	Hantaviruses induce cytopathic effects and apoptosis in continuous human embryonic kidney cells. <i>Journal of General Virology</i> , 2003, 84, 2197-2202.	2.9	39

#	ARTICLE	IF	CITATIONS
127	Therapeutics of Ebola Hemorrhagic Fever: Whole-Genome Transcriptional Analysis of Successful Disease Mitigation. <i>Journal of Infectious Diseases</i> , 2011, 204, S1043-S1052.	4.0	38
128	Detailed Analysis of the African Green Monkey Model of Nipah Virus Disease. <i>PLoS ONE</i> , 2015, 10, e0117817.	2.5	38
129	Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007595.	3.0	38
130	Framework for Leadership and Training of Biosafety Level 4 Laboratory Workers. <i>Emerging Infectious Diseases</i> , 2008, 14, 1685-1688.	4.3	38
131	FGI-104: a broad-spectrum small molecule inhibitor of viral infection. <i>American Journal of Translational Research (discontinued)</i> , 2009, 1, 87-98.	0.0	38
132	Countermeasures to the Bioterrorist Threat of Smallpox. <i>Current Molecular Medicine</i> , 2005, 5, 817-826.	1.3	37
133	Transcriptional Profiling of the Immune Response to Marburg Virus Infection. <i>Journal of Virology</i> , 2015, 89, 9865-9874.	3.4	37
134	The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. <i>Thrombosis and Haemostasis</i> , 2005, 94, 254-61.	3.4	36
135	Transcriptional Profiling of the Circulating Immune Response to Lassa Virus in an Aerosol Model of Exposure. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2171.	3.0	36
136	The Master Regulator of the Cellular Stress Response (HSF1) Is Critical for Orthopoxvirus Infection. <i>PLoS Pathogens</i> , 2014, 10, e1003904.	4.7	35
137	Ebola epidemic—Liberia, March–October 2014. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 1082-6.	15.1	35
138	Pathogen-Host Associations and Predicted Range Shifts of Human Monkeypox in Response to Climate Change in Central Africa. <i>PLoS ONE</i> , 2013, 8, e66071.	2.5	34
139	Necrotizing Scleritis, Conjunctivitis, and Other Pathologic Findings in the Left Eye and Brain of an Ebola Virus-Infected Rhesus Macaque (<i>Macaca mulatta</i>) With Apparent Recovery and a Delayed Time of Death. <i>Journal of Infectious Diseases</i> , 2016, 213, 57-60.	4.0	34
140	Real-time Monitoring of Cardiovascular Function in Rhesus Macaques Infected With Zaire ebolavirus. <i>Journal of Infectious Diseases</i> , 2011, 204, S1000-S1010.	4.0	33
141	Nonhuman Primate Models of Ebola Virus Disease. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 171-193.	1.1	33
142	CD26/DPP4 Cell-Surface Expression in Bat Cells Correlates with Bat Cell Susceptibility to Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection and Evolution of Persistent Infection. <i>PLoS ONE</i> , 2014, 9, e112060.	2.5	33
143	Modeling [18F]-FDG lymphoid tissue kinetics to characterize nonhuman primate immune response to Middle East respiratory syndrome-coronavirus aerosol challenge. <i>EJNMMI Research</i> , 2015, 5, 65.	2.5	32
144	Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. <i>PLoS ONE</i> , 2018, 13, e0194880.	2.5	31

#	ARTICLE	IF	CITATIONS
145	In vitro inhibition of monkeypox virus production and spread by Interferon- β . <i>Virology Journal</i> , 2012, 9, 5.	3.4	30
146	How NETosis could drive "Post-COVID-19 syndrome" among survivors. <i>Immunology Letters</i> , 2020, 228, 35-37.	2.5	30
147	Emerging Disease or Diagnosis?. <i>Science</i> , 2012, 338, 750-752.	12.6	29
148	Lassa and Marburg viruses elicit distinct host transcriptional responses early after infection. <i>BMC Genomics</i> , 2014, 15, 960.	2.8	29
149	Chikungunya and O β nyong-nyong Viruses in Uganda: Implications for Diagnostics. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz001.	0.9	29
150	Proportionate mortality among union members employed at three Texas refineries. , 1998, 33, 327-340.		28
151	Ultrastructural study of Rift Valley fever virus in the mouse model. <i>Virology</i> , 2012, 431, 58-70.	2.4	28
152	Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. <i>PLoS ONE</i> , 2016, 11, e0166318.	2.5	28
153	The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease. <i>Journal of Infectious Diseases</i> , 2018, 218, S588-S591.	4.0	28
154	Progression of Pathogenic Events in Cynomolgus Macaques Infected with Variola Virus. <i>PLoS ONE</i> , 2011, 6, e24832.	2.5	26
155	Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. <i>Journal of Virological Methods</i> , 2018, 255, 84-90.	2.1	26
156	Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2015, 89, 9875-9885.	3.4	24
157	Natural History of Aerosol Exposure with Marburg Virus in Rhesus Macaques. <i>Viruses</i> , 2016, 8, 87.	3.3	24
158	Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006474.	3.0	24
159	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2021, 73, 1849-1856.	5.8	24
160	Evidence against an Important Role for Infectivity-Enhancing Antibodies in Ebola Virus Infections. <i>Virology</i> , 2002, 293, 15-19.	2.4	22
161	Development of Vaccinia reporter viruses for rapid, high content analysis of viral function at all stages of gene expression. <i>Antiviral Research</i> , 2011, 91, 72-80.	4.1	22
162	Transcriptional Correlates of Disease Outcome in Anticoagulant-Treated Non-Human Primates Infected with Ebolavirus. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3061.	3.0	22

#	ARTICLE	IF	CITATIONS
163	The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 30687-30698.	7.1	22
164	Identification of a Broad-Spectrum Inhibitor of Viral RNA Synthesis: Validation of a Prototype Virus-Based Approach. <i>Chemistry and Biology</i> , 2013, 20, 424-433.	6.0	21
165	In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus. <i>Journal of Infectious Diseases</i> , 2018, 218, S592-S596.	4.0	21
166	High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona. <i>Scientific Reports</i> , 2017, 7, 5886.	3.3	20
167	The NIAID Integrated Research Facility at Frederick, Maryland: a unique international resource to facilitate medical countermeasure development for BSL-4 pathogens. <i>Pathogens and Disease</i> , 2014, 71, 213-218.	2.0	19
168	Use of Existing Diagnostic Reverse-Transcription Polymerase Chain Reaction Assays for Detection of Ebola Virus RNA in Semen. <i>Journal of Infectious Diseases</i> , 2016, 213, 1237-1239.	4.0	19
169	Fully Human Immunoglobulin G From Transchromosomal Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. <i>Journal of Infectious Diseases</i> , 2018, 218, S636-S648.	4.0	19
170	Critical role for cholesterol in Lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1. <i>PLoS Pathogens</i> , 2018, 14, e1007322.	4.7	18
171	Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein. <i>Archives of Virology</i> , 2011, 156, 1877-1881.	2.1	17
172	New Insights Into Marburg Virus Disease Pathogenesis in the Rhesus Macaque Model. <i>Journal of Infectious Diseases</i> , 2018, 218, S423-S433.	4.0	17
173	Virus-Receptor Interactions and Interspecies Transfer of a Mouse Hepatitis Virus. <i>Advances in Experimental Medicine and Biology</i> , 1998, 440, 33-41.	1.6	17
174	Carcinogenicity of Gasoline: A Review of Epidemiological Evidence. <i>Annals of the New York Academy of Sciences</i> , 1997, 837, 53-76.	3.8	16
175	High depth, whole-genome sequencing of cholera isolates from Haiti and the Dominican Republic. <i>BMC Genomics</i> , 2012, 13, 468.	2.8	16
176	In Vivo Activity of Amodiaquine against Ebola Virus Infection. <i>Scientific Reports</i> , 2019, 9, 20199.	3.3	16
177	Detection and identification of Variola virus in fixed human tissue after prolonged archival storage. <i>Laboratory Investigation</i> , 2004, 84, 41-48.	3.7	15
178	Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans. <i>Journal of Infectious Diseases</i> , 2018, 218, S486-S495.	4.0	15
179	Quantification of Viral and Host Biomarkers in the Liver of Rhesus Macaques. <i>American Journal of Pathology</i> , 2020, 190, 1449-1460.	3.8	15
180	Kikwit Ebola Virus Disease Progression in the Rhesus Monkey Animal Model. <i>Viruses</i> , 2020, 12, 753.	3.3	15

#	ARTICLE	IF	CITATIONS
181	Identification of a Pyridopyrimidinone Inhibitor of Orthopoxviruses from a Diversity-Oriented Synthesis Library. <i>Journal of Virology</i> , 2012, 86, 2632-2640.	3.4	14
182	Lack of Effect of Lamivudine on Ebola Virus Replication. <i>Emerging Infectious Diseases</i> , 2015, 21, 550-552.	4.3	14
183	Assessment and Optimization of the GeneXpert Diagnostic Platform for Detection of Ebola Virus RNA in Seminal Fluid. <i>Journal of Infectious Diseases</i> , 2016, 215, jiw599.	4.0	14
184	Natural History of Aerosol Induced Lassa Fever in Non-Human Primates. <i>Viruses</i> , 2020, 12, 593.	3.3	14
185	Accelerating Vaccine Development During the 2013–2016 West African Ebola Virus Disease Outbreak. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 229-261.	1.1	14
186	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. <i>Microorganisms</i> , 2021, 9, 566.	3.6	13
187	State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus. <i>Journal of Infectious Diseases</i> , 2015, 212, S84-S90.	4.0	12
188	PREVAIL I Cluster Vaccination Study With rVSV ^Δ G-ZEBOV-GP as Part of a Public Health Response in Liberia. <i>Journal of Infectious Diseases</i> , 2019, 219, 1634-1641.	4.0	12
189	Full-Genome Sequence of Human Betacoronavirus 2c Jordan-N3/2012 after Serial Passage in Mammalian Cells. <i>Genome Announcements</i> , 2014, 2, .	0.8	11
190	Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samples. <i>PLoS ONE</i> , 2019, 14, e0221407.	2.5	11
191	Deep Learning for Automated Liver Segmentation to Aid in the Study of Infectious Diseases in Nonhuman Primates. <i>Academic Radiology</i> , 2021, 28, S37-S44.	2.5	11
192	Interferon- β and Interferon- γ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays. <i>Journal of Infectious Diseases</i> , 2017, 215, 1416-1420.	4.0	9
193	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. <i>Frontiers in Immunology</i> , 2021, 12, 682120.	4.8	9
194	Partnership for Research on Ebola VACCination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. <i>Trials</i> , 2021, 22, 86.	1.6	9
195	Expanded Histopathology and Tropism of Ebola Virus in the Rhesus Macaque Model. <i>American Journal of Pathology</i> , 2022, 192, 121-129.	3.8	9
196	Genome Sequence of Bivens Arm Virus, a Tibrovirus Belonging to the Species Tibrogargan virus (<i>Tj ETQq0 0 0 rgBT</i>). <i>Overlock</i> , 10 Tf 50	0.8	8
197	The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 218, S690-S697.	4.0	8
198	Ebola Virus Isolation Using Huh-7 Cells has Methodological Advantages and Similar Sensitivity to Isolation Using Other Cell Types and Suckling BALB/c Laboratory Mice. <i>Viruses</i> , 2019, 11, 161.	3.3	8

#	ARTICLE	IF	CITATIONS
199	Peripheral Neuronopathy Associated With Ebola Virus Infection in Rhesus Macaques: A Possible Cause of Neurological Signs and Symptoms in Human Ebola Patients. <i>Journal of Infectious Diseases</i> , 2020, 222, 1745-1755.	4.0	8
200	Immunogenicity of rVSV Δ G-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	8
201	Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals. <i>Biology Direct</i> , 2016, 11, 25.	4.6	7
202	Human Biliary Glycoproteins Function as Receptors for Interspecies Transfer of Mouse Hepatitis Virus. <i>Advances in Experimental Medicine and Biology</i> , 1998, 440, 43-52.	1.6	7
203	Enhancing laboratory capacity during Ebola virus disease (EVD) heightened surveillance in Liberia: lessons learned and recommendations. <i>Pan African Medical Journal</i> , 2019, 33, 8.	0.8	7
204	Association of Lower Exposure Risk With Paucisymptomatic/Asymptomatic Infection, Less Severe Disease, and Unrecognized Ebola Virus Disease: A Seroepidemiological Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac052.	0.9	7
205	Rhesus Macaque CODEX Multiplexed Immunohistochemistry Panel for Studying Immune Responses During Ebola Infection. <i>Frontiers in Immunology</i> , 2021, 12, 729845.	4.8	7
206	Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 4. Medical Imaging Procedures. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	6
207	Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 3. Aerobiology. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	6
208	Previremic Identification of Ebola or Marburg Virus Infection Using Integrated Host-Transcriptome and Viral Genome Detection. <i>MBio</i> , 2020, 11, .	4.1	6
209	Efficacy and Safety Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease: 12-Month Results From the PREVAIL VII Study. <i>Translational Vision Science and Technology</i> , 2021, 10, 32.	2.2	6
210	Receptor Homologue Scanning Functions in the Maintenance of MHV-A59 Persistence in Vitro. <i>Advances in Experimental Medicine and Biology</i> , 1998, 440, 743-750.	1.6	6
211	Nonhuman Transferrin Receptor 1 Is an Efficient Cell Entry Receptor for Ocozocoautla de Espinosa Virus. <i>Journal of Virology</i> , 2013, 87, 13930-13935.	3.4	5
212	Systems kinomics for characterizing host responses to high-consequence pathogens at the NIH/NIAID Integrated Research Facility-Frederick. <i>Pathogens and Disease</i> , 2014, 71, 190-198.	2.0	4
213	Filoviruses Infect Rhesus Macaque Synoviocytes in Vivo and Primary Human Synoviocytes in Vitro. <i>American Journal of Pathology</i> , 2020, 190, 1867-1880.	3.8	4
214	Probing the Virus Host Interaction in High Containment: An Approach Using Pooled Short Hairpin RNA. <i>Assay and Drug Development Technologies</i> , 2015, 13, 34-43.	1.2	3
215	Ebola virus is unlikely to become endemic in West Africa. <i>Nature Microbiology</i> , 2016, 1, 16007.	13.3	3
216	Viral hemorrhagic fevers. , 2010, , 1247-1252.		3

#	ARTICLE	IF	CITATIONS
217	Detecting Pathogen Exposure During the Non-symptomatic Incubation Period Using Physiological Data: Proof of Concept in Non-human Primates. <i>Frontiers in Physiology</i> , 2021, 12, 691074.	2.8	2
218	Detailed analysis of the pathologic hallmarks of Nipah virus (Malaysia) disease in the African green monkey infected by the intratracheal route. <i>PLoS ONE</i> , 2022, 17, e0263834.	2.5	2
219	Increased Likelihood of Detecting Ebola Virus RNA in Semen by Using Sample Pelleting. <i>Emerging Infectious Diseases</i> , 2021, 27, 1239-1241.	4.3	1
220	Detection and identification of Variola virus in fixed human tissue after prolonged archival storage. <i>Laboratory Investigation</i> , 2004, 84, 41-48.	3.7	1
221	Cocktail party: Low-dose antibody combinations deliver pan-ebolavirus protection. <i>Cell</i> , 2022, 185, 943-945.	28.9	1
222	Simplifying the Estimation of Diagnostic Testing Accuracy Over Time for High Specificity Tests in the Absence of a Gold Standard. <i>Biometrics</i> , 2023, 79, 1546-1558.	1.4	0